LV12358B - 7-(aizvietoti)-9-(aizvietoti glicil)-amido-6-demetil-6-deoksitetraciklīni - Google Patents

7-(aizvietoti)-9-(aizvietoti glicil)-amido-6-demetil-6-deoksitetraciklīni Download PDF

Info

Publication number
LV12358B
LV12358B LVP-99-112A LV990112A LV12358B LV 12358 B LV12358 B LV 12358B LV 990112 A LV990112 A LV 990112A LV 12358 B LV12358 B LV 12358B
Authority
LV
Latvia
Prior art keywords
group
amino
alkyl
substituted
dioxo
Prior art date
Application number
LVP-99-112A
Other languages
English (en)
Other versions
LV12358A (lv
Inventor
Phaik-Eng Sum
Ving J. Lee
Raymond T. Testa
Original Assignee
American Cyanamid Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Company filed Critical American Cyanamid Company
Publication of LV12358A publication Critical patent/LV12358A/lv
Publication of LV12358B publication Critical patent/LV12358B/lv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • C07D295/30—Nitrogen atoms non-acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
    • C07C2603/44—Naphthacenes; Hydrogenated naphthacenes
    • C07C2603/46—1,4,4a,5,5a,6,11,12a- Octahydronaphthacenes, e.g. tetracyclines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Seasonings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Spinning Or Twisting Of Yarns (AREA)
  • Moulding By Coating Moulds (AREA)
  • Fats And Perfumes (AREA)
  • Detergent Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Claims (8)

  1. LV 12358 FORMULA 1. Savienojums ar formulu: 5 R N < CH0 >
    W OH 0 OH 0 0 R N(CH,)
    hhch2n< R kur R ir halogēns, kas izvēlēts no rindas: broms, hlors, fluors un jods; vai R-NR1R2 un, kad R = -NR1R2 un R1 = ūdeņradis, īo R2 = metil-, etil-, n-propil-, 1-metiletil-, n-butil-, 1-metilpropil-, 2-metilpropil- vai 1,1 -dimetiletilgrupa; un kad R1 = metil- vai etilgrupa, R2 = metil-, etil-, n-propil-, 1-metiletil-, n-butil-, 1-metilpropil- vai 2-metilpropilgrupa; 15 un kad R1 = n-propilgrupa, R2 = n-propil-, 1-metiletil-, n-butil-, 1-metilpropil- vai 2-metilpropilgrupa; un kad R1 = 1-metiletilgrupa, R2 =n-butil-, 1-metilpropil- vai 2-metilpropilgrupa; un kad R1 = n-butilgrupa, 20 R2 =n-butil-, 1-metilpropil- vai 2-metilpropilgrupa; un kad R1 = 1-metilpropilgrupa, R2 = 2-metilpropilgrupa; R3 ir izvēlēts no rindas: ūdeņradis, lineāra vai sazarota (C4-C8) alkilgrupa, kas izvēlēta no rindas: butil-, izobutil-, pentil-, heksil-, heptil- un oktilgrupa; a- 2 merkapto(CrC4)alkilgrupa, kas izvēlēta no merkaptometil-, a-merkaptoetil-, a-merkapto-1-metiletil- un a-merkaptopropilgrupa; a-hidroksi(Ci-C4)alkilgrupa, kas izvēlēta no rindas: hidroksimetil-, a-hidroksietil-, ct-hidroksi-1-metiletil- un a-hidroksipropilgrupa; karboksi(Cļ-C8)alkilgrupa; 5 (C6-Ci0)arilgrupa, kas izvēlēta no rindas: fenil-, α-naftil- un β-naftilgrupa; aizvietota(C6-C10)arilgrupa (aizvietotājs izvēlēts no rindas: hidroksigrupa, halogēns, (Cļ-C^alkoksi-, trihalo(Ci-C3)alkil-, nitro-, amino-, ciano-, (Cr C4)alkoksikarbonil-, (Ci-C3)alkilamino- un karboksilgrupa); (C7-C9)aralkilgrupa, kas izvēlēta no rindas: benzil-, 1-feniletil-, 2-feniletil un ίο fenilpropilgrupa; aizvietota (C7-C9)aralkilgrupa [aizvietotājs izvēlēts no rindas: halogēns, (Cr C4)alkil-, nitro-, hidroksi-, amino-, vien- vai div- aizvietota (Cr C4)alkilaminogrupa, (Ci-C4)alkoksi-, (Ci-C4)alkilsulfonil-, ciano- un karboksilgrupa]; 15 R4 ir izvēlēts no: ūdeņradis un (CrC6)alkilgrupa, kas izvēlēta no rindas: metil-, etil-, propil-, izopropil-, butil-, izobutil-, pentil- un heksilgrupa; kad R3 nav vienāds ar R4, asimetriskā oglekļa atoma stereoķīmija (oglekļa atoms ar aizvietotāju W) var būt racemāts (DL) vai atsevišķs enantiomērs (L vai D); 20 W ir izvēlēts no hidroksilaminogrupas; (C7-C12) lineāra vai sazarota alkil-vienaizvietota aminogrupa, kur aizvietotājs ir izvēlēts no rindas: heptil-, oktil-, nonil-, decil-, undecil-, dodecilgrupa un no minētās lineārās vai sazarotās alkil-vienaizvietotās aminogrupas diastereomēri un enantiomēri; (CrC4) lineāra vai sazarota fluoroalkilaminogrupa ir izvēlēta no rindas: trifluorometil-, 2,2,2-25 trifluoroetil-, 3,3,3-trifluoropropil-, 3,3,3,2,2-pentafluoropropil-, 2,2-difluoropropil-, 4,4,4-trifluorobutil- un 3,3-di-fluorobutilgrupa; [(C4-C-io)cikloalkil]alkil-vienaizvietota aminogrupa, kur aizvietotājs ir izvēlēts no rindas: (ciklopropil)metil-, (ciklopropil)etil-, (ciklobutil)metil-, (trans-2-metilciklopropil)metil- un (cis-2-metilciklobutil)metilgrupa; (C3-C10) alkenil- un 30 alkinil- vienaizvietota aminogrupa, kur aizvietotājs ir izvēlēts no rindas: alil-, 3-butenil-, 2-butenil- (cis vai trans), 2-pentenil-, propinil-, 4-oktenil-, 2,3-dimetil-2-butenil-, 3-metil-butenil-, 2-ciklopentenil- un 2-cikloheksenilgrupa; (C7-C9)aralkilgrupas aizvietotājs ir izvēlēts no rindas: benzil-, 2-feniletil-, 1-feniletil-, 2-(naftil)metil-, 1 -(naftil)metil- un fenilpropilgrupa; aizvietota(C6-C10)aril- 3 LV 12358 vienaizvietota aminogrupa [aizvietotājs ir izvēlēts no rindas: (Ci-C5)acil-, (Ci-C5)acilamino-, (CrC4)alkilgrupa, vienaizvietota vai divaizvietota (Cr C8)acilamino-, (CrC4)alkoksi-, (CrC4)alkoksikarbonil-, (CrC4)alkilsulfonil-, amino-, karboksil-, cianogrupa, halogēns, hidroksi-, nitro- un trihalogēn(Ci-C3)alkilgrupa]; lineāra vai sazarota simetriski divaizvietota alkilaminogrupa, kur aizvietotājs ir izvēlēts no rindas: dibutil-, diizobutil-, di-s-butil-, dipentil-, diizopentil-, di-s-pentil-, diheksil-, diizoheksil- un di-s-heksiigrupa; simetriski divaizvietota (C6-Ci4) cikloalkilaminogrupa, kur aizvietotājs ir izvēlēts no rindas: diciklopropil-, diciklobutil-, diciklopentil-, di(diciklopropil)metil-, dicikloheksil- un dicikloheptilgrupa; lineāra vai sazarota nesimetriski divaizvietota (C3-Ci4)alkilaminogrupa, kur kopējais oglekļa atomu skaits aizvietotājos ir lielāks par 14; nesimetriski divaizvietota (C4-Ci4)cikloalkilaminogrupa, kur kopējais oglekļa atomu skaits aizvietotājos nav lielāks par 14; (C2-C8)azacikloalkilgrupa un aizvietota (C2-C8)azacikloalkilgrupa, kur aizvietotājs ir izvēlēts no rindas: 4-metilpiperidinil-, 4-hidroksipiperidinil-, 4-(hidroksimetil)piperidinil-, 4-(aminometil)piperidinil-, 4-(aminoetil)piperidinil-, cis-3,4-dimetilpirolidinil-, trans-3,4-dimetilpirolidinil-, 2-azabiciklo[2.1.1]heks-2-il-, 5-azabiciklo[2.1.1]heks-5-il-2-azabiciklo[2.2.1 ]hept-2-il-, 7-azabiciklo[2.2.1 ]hept-7-il-, 2-azabiciklo[2.2.2]okt-2-ilgrupa un minēto (C2-C8)azacikloalkil- un aizvietotas (C2-C8)azacikloalkilgrupu diastereomēri un enantiomēri; aizvietota 1-azaoksacikloalkilgrupa, kur aizvietotājs ir izvēlēts no rindas: 2-(CrC3)alkilmorfolinil-,3-(Ci-C3)alkilizoksazolidinil-, tetrahidrooksazinil- un 3,4-dihidrooksazinilgrupa; [1,nļ-diazacikloalkil- un aizvietota [1,n]-diazacikloalkilgrupas, kas izvēlētas no rindas: piperazinil-, 2-(CrC3)alkilpiperazinil-, 4-(CrC3)alkilpiperazinil-, 2,4-dimetilpiperazinil-, 4-(CrC4)alkoksipiperazinil-, 4-(C6-Cio)ariloksipiperazinil-, 4-hidroksipiperazinil-, 2,5-diazabiciklo[2.2.1]hept-2-il-, 2,5-diaza-5-metilbiciklo[2.2.1]hept-2-il-, 2,3-diaza-3-metilbiciklo[2.2.2]okt-2-il-, 2,5-diaza-5,7-dimetilbiciklo[2,2.2]okt-2-ilgrupa un minēto [1,n]-diazacikloalkil- un aizvietotas [1,n]-diazacikloalkilgrupas diastereomēriem vai enantiomēriem; 1-azatiacikloalkil- un aizvietota 1-azatiacikloalkilgrupas, kas izvēlētas no rindas: tiomorfolinil-, 2-(CrC3)alkiltiomorfolinil- un 3-(C3-C6)cikloalkiltiomorfolinilgrupa; N-azolil- un aizvietota N-azolilgrupa, kas izvēlētas rio rindas: 1-imidazolil-, 2-(Ci-C3)alkil-1 -imidazolil-, 3-(Ci-C3)alkil-1 -imidazolil-, 1-pirolil-, 2-(Ci-C3)alkil-1- Λ pirolil-, 3-(Ci-C3)alkil-1 -pirolil-, 1-pirazoiil-, 3-(CrC3)-alkil-1-pirazolil-, indoil-, 1-(1,2,3-triazolil)-, 4-(Ci-C3)alkil-1 -(1,2,3-triazoIil)-, 5-(Ci-C3)alkil-1-(1,2,3-triazolil)-, 4- (1,2,4-triazolil)-, 1-tetrazolil-, 2-tetrazolil- un benzimidazolilgrupa; (heterocikla)aminogrupa, kur minētais heterocikls ir izvēlēts no rindas: 2- vai 3-furanil-, 2- vai 3-tienil, 2-, 3- vai 4-piridil-, 2- vai 5-piridazinil-, 2-pirazinil-, 2-(imidazolil)-, (benzimidazolil)-, un (benzotiazolil)grupa un aizvietota (heterocikla)aminogrupa (aizvietotājs ir izvēlēts no lineāras vai sazarotas (Cr C6)alkilgrupas); (heterocikla)metilaminogrupa, kas izvēlēta no rindas: 2- vai 3-furilmetilamino-, 2- vai 3-tienilmetil-amino-, 2-, 3- vai 4-piridilmetilamino-, 2- vai 5- piridazinilmetilamino-, 2-pirazinilmetilamino-, 2-(imidazolil)metilamino-, (benzimidazolil)metilamino-, un (benzotiazolil)metilaminogrupa, un minētās aizvietotās (heterocikla)metilaminogrupas (aizvietotājs ir izvēlēts no sazarotas (C-i-Cejalkilgrupas); karboksi(C2-C4)alkilaminogrupa, kas izvēlēta no rindas: aminoetiķ-, a-aminopropion-, β-aminopropion-, a-aminosviest-, β-aminosviestskābe un minētās karboksi(C2-C4)alkilaminogrupas enantiomēri; 1,1-divaizvietota hidrazīnogrupa, kas izvēlēta no rindas: 1,1-dimetilhidrazino-, N-aminopiperidinil-, 1,1-dietilhidrazīno- un N-aminopirolidinilgrupa; (Cr C4)alkoksigrupas aizvietotājs ir izvēlēts no rindas: metoksi-, etoksi-, n-propoksi-, 1- metiletoksi-, n-butoksi-, 2-metilpropoksi- un 1,1-dimetiletoksigrupa; (C3-Ca)cikloalkoksigrupa, kas izvēlēta no rindas: ciklopropoksi-, trans-1,2-dimetilciklopropoksi-, cis-1,2-dimetilciklopropoksi-, ciklobutoksi-, ciklopentoksi-, cikloheksoksi-, cikloheptoksi-, ciklooktoksi-, biciklo[2.2.1]hept-2-iloksi-, biciklo[2.2.2]okt-2-iloksigrupa un minētās (C3-C8)cikloalkoksigrupas diastereomēriem un enantiomēriem; (Ce-Ciojariloksiaminogrupa, kas izvēlēta no rindas: fenoksiamino-, 1-naftiloksiamino- un 2-naftiloksiaminogrupa; (C7-Cn)arilalkoksiaminogrupas aizvietotājs, kas izvēlēts no rindas: benzioloksi-, 2-feniletoksi-, 1-feniletoksi-, 2-(naftil)metoksi-, 1-(naftil)metoksi-, un fenilpropoksigrupa; [β vai y-(CrC3)acilamido]alkilaminogrupas aizvietotājs, kas izvēlēts no rindas: 2-(formamido)etil-, 2-(acetamido)etil-, 2-(propionilamido)etil-, 2- (acetamido)propil-, 2-(formamido)propilgrupa un minētās [β vai y-(Cr C3)acilamido]alkilaminogrupas enantiomēri; β vai y-(Cr C3)alkoksialkilaminogrupas aizvietotājs, kas izvēlēts no rindas: 2-metoksietil-, 2-etoksietil-, 2,2-dietoksietil-, 2-metoksipropil-, 3-metoksipropil-, 3-etoksipropil-, 3,3-dietoksipropilgrupa un minētās β vai y-(C1-C3)alkoksialkilaminogrupas 5 LV 12358 enantiomēri; β, γ vai 6-(C2-C4)hidroksialkilaminogrupas aizvietotājs, kas izvēlēts no rindas: 2-hidroksietil-, 2-hidroksipropil-, 3-hidroksipropil- un 4-hidroksibutilgrupa; vai R3 un W kopā ir izvēlēti no -(CH2)n(R5)N-, n=3-4, un 5 -CH2CH(OH)CH2(R5)N-, kur R5 izvēlēts no ūdeņraža un (CrC3)acilgrupas, karbonskābes atlikums ir izvēlēts no rindas: formil-, acetil-, propionilgrupa un (C2-C3)haloacilgrupa, kas izvēlēta no rindas: hloroacetil-, bromoacetil-, trifluoroacetil-, 3,3,3-trifluoropropionil- un 2,3,3-trifluoropropionilgrupa; R6 ir izvēlēts no: ūdeņradis, lineāra vai sazarota (CrC3)alkilgrupa, kas izvēlēta īo no rindas: metil-, etil-, n-propil- vai 1-metiletilgrupa; (C6-Ci0)arilgrupa, kas izvēlēta no rinas: fenil-, α-naftil- vai β-naftilgrupa; tāda (C7-C9)aralkilgrupa kā: benzil-, 1-feniletil-, 2-feniletil- vai fenilpropilgrupa; heterocikliska grupa, kas izvēlēta no aromātiska vai piesātināta pieclocekļu cikla ar vienu N, 0, S vai Se heteroatomu, un kura, pēc izvēles, satur benzo vai pirido ciklu, kurš, turklāt, 15 kondensēts sekojoši:
    vai
    Z = N, O, S vai Se 20 tāda kā: pirolil-, N-metilindolil-, indolil-, 2-pirolidinil-, 3-pirolidinil-, 2-pirolinil-, tetrahidrofuranil-, furanil-, benzofuranil-, tetrahidrotienil-, tienil-, benzotienil- vai selēnazolilgrupa, vai aromātiska pieclocekļu cikla ar diviem N, 0, S vai Se heteroatomiem, un kurš, pēc izvēles, satur benzo vai pirido ciklu, kurš, turklāt, 25 kondensēts sekojoši:
    vai
    Z vai Z1 = N, O, S vai Se 6 tāda kā: imidazolil-, pirazolil-, benzimidazolil-, oksazolil-, benzoksazolil-, indazolil-, tiazolil-, benzotiazolil-, 3-alkil-3H-imidazo[4,5-b]piridil- vai piridilimidazolilgrupa, vai aromātiska pieclocekļu cikla ar vienu vai diviem N, O, S vai Se heteroatomiem un blakus esošu pievienotu O heteroatomu:
    A A (A ir izvēlēts no: ūdeņradis; lineāra vai sazarota (CrC4)alkilgrupa, C6-arilgrupa; aizvietota C6-arilgrupa (aizvietotājs ir izvēlēts no rindas: halo(C1-C4)alkoksi-, trihalo(CrC3)alkil-, nitro-, amino-, ciano-, (Ci-C4)alkoksikarbonilgrupa, (Ci-C3)alkilamino- vai karboksilgrupa); (C7-C9)aralkilgrupa, kas izvēlēta no rindas: benzil-, 1-feniletil-,2-feniletil-vai fenilpropilgrupa, tāda kā: γ-butirolaktāms, γ-butirolaktons, imidazolidinons vai N-aminoimidazolidinons, vai aromātiska sešlocekļu cikla ar vienu līdz trijiem N heteroatomiem, tāda kā: piridil-, piridazinil-, pirazinil-, simetriska triazinil-, nesimetriska triazinil-, pirimidinil- vai (Ci-C3)alkiltiopiridazinil, vai piesātināta sešlocekļu cikla ar vienu vai diviem N, O, S vai Se heteroatomiem un blakus esošu pievienotu O heteroatomu, tāds kā: 2,3-diokso-1-piperazinil-, 4-etil-2,3-diokso-1 -piperazinil-, 4-metil-2,3-diokso-1-piperazinil-, 4-ciklopropil-2-diokso-1-piperazinil-, 2-dioksomorfolinil-, 2-dioksotiomorfolinilgrupa; vai -(CH2)nCOOR8, kur n=0-4 un R8 ir izvēlēts no: ūdeņradis, lineāra vai sazarota (CrC3)alkilgrupa, kas izvēlēta no rindas: metil-, etil-, n-propil- vai 1-metiletilgrupa; vai (Ce-Cio)arilgrupa, kas izvēlēta no rindas: fenil-, α-naftil- vai β-naftilgrupa; R7 ir izvēlēts no: ūdeņradis, lineāra vai sazarota (Ci-C3)alkilgrupa, kas izvēlēta no rindas: metil-, etil-, n-propil- vai 1-metiletilgrupa; vai (Ce-Ciojarilgrupa, kas izvēlēta no rindas: fenil-, α-naftil- vai β-naftilgrupa; tāda (C7-Cg)aralkilgrupa kā: benzil-, 1-feniletil-, 2-feniletil-vai fenilpropilgrupa; heterocikliska grupa, kas izvēlēta no aromātiska vai piesātināta pieclocekļu cikla ar vienu N, O, S vai Se heteroatomu, un kura, pēc izvēles, satur benzo vai pirido ciklu, kurš, turklāt, kondensēts sekojoši: LV 12358 7'V vai
    Z = N, O, S vai Se tāda kā: pirolil-, N-metilindolil-, indolil-, 2-pirolidinil-, 3-pirolidinil-, 2-pirolinil-, tetrahidrofuranil-, furanil-, benzofuranil-, tetrahidrotienil-, tienil-, benzotienil- vai selēnazolilgrupa, vai aromātiska pieclocekļu cikla ar diviem N, 0, S vai Se heteroatomiem, un kurš, pēc izvēles, satur benzo vai pirido ciklu, kurš, turklāt, kondensēts sekojoši:
    Z vai Z1 = N, 0, S vai Se tāda kā: imidazolil-, pirazolil-, benzimidazolil-, oksazolil-, benzoksazolil-, indazolil-, tiazolil-, benzotiazolil-, 3-alkil-3H-imidazo[4,5-b]piridil- vai piridilimidazolilgrupa, vai aromātisks pieclocekļu cikls ar vienu vai diviem N, O, S vai Se heteroatomiem un blakus esošu pievienotu O heteroatomu: vai 0 '0 · N r ' N 0 I I A A (A ir izvēlēts no: ūdeņradis; lineāra vai sazarota (C-i-C^alkilgrupa, C6-arilgrupa; aizvietota C6-arilgrupa (aizvietotājs ir izvēlēts no rindas: halo(CrC4)alkoksi-, trihalo(CrC3)alkil-, nitro-, amino-, ciano-, (CrC^alkoksikarbonilgrupa, (Cr C3)alkilamino- vai karboksilgrupa); (C7-Cg)aralkilgrupa, kas izvēlēta no rindas: benzil-, 1-feniletil-,2-feniletil-vai fenilpropilgrupa), tāda kā: γ-butirolaktāms, γ-butirolaktons, imidazolidinons vai N-aminoimidazolidinons, vai aromātiska sešlocekļu cikla ar vienu līdz trijiem N 8 heteroatomiem, tāda kā: piridil-, piridazinil-, pirazinil-, simetriska triazinil-, nesimetriska triazinil-, pirimidinil- vai (Cn-C3)alkiltiopiridazinil, vai piesātināta sešlocekļu cikla ar trijiem N, O, S vai Se heteroatomiem un blakus esošu pievienotu O heteroatomu, tāds kā: 2,3-diokso-1-piperazinil-, 4-etil-2,3-diokso-1-piperazinil-, 4-metil-2,3-diokso-1-piperazinil-, 4-ciklopropil-2-diokso-1- p piperazinil-, 2-dioksomorfolinil-, 2-dioksotiomorfolinilgrupa; vai -(CH2)nCOOR , kur n=0-4 un R8 ir izvēlēts no: ūdeņradis, lineāra vai sazarota (Ci-C3)alkilgrupa, kas izvēlēta no rindas: metil-, etil-, n-propil- vai 1-metiletilgrupa; vai (Ce-C-io)arilgrupa, kas izvēlēta no rindas: fenil-, α-naftil- vai β-naftilgrupa; ar nosacījumu, ka R6 un R7 abi nevar būt ūdeņradis; vai R6 un R7 kopā ir -(CH2)2B(CH2)2-, kur B ir izvēlēts no rindas: (CH2)n un n=0- 1, -NH, -N(CrC3) alkil[lineāra vai sazarotajgrupa, -N(Ci-C4)alkoksigrupa, skābeklis, sērs vai aizvietoti radnieciski savienojumi, kas izvēlēti no rindas: (L vai D) prolīns, etil(L vai Djprolināts, morfolīns, pirolidīns vai piperidīns; un farmaceitiski pieņemamiem organiskiem un neorganiskiem sāļiem vai metālu kompleksajiem savienojumiem, ar nosacījumu, ka gadījumā, ja R3 ir R4 abi ir ūdeņradis, tad W ir savādāks nekā benzilamino-,1-imidazolil-, 1-pirolil-, 1-(1,2,3-triazolil)- vai 4-(1,2,4-triazolil)grupa. 9 LV 12358 C5)cikloalkil]alkil- vienaizvietota aminogrupa, kur aizvietotājs ir izvēlēts no: (ciklopropil)metil- un (ciklopropil)etilgrupa; (C3-C4) alkenil- un alkinil-vienaizvietota aminogrupa, kur aizvietotājs ir izvēlēts no: alil un propinilgrupa; (C2-C7)azacikloalkilgrupa un aizvietota (C2-C7)azacikloalkilgrupa, kur aizvietotājs ir izvēlēts no rindas: 4-metilpiperidinil-, 4-hidroksipiperidinil- un 4-(hidroksimetil)piperidinilgrupa; aizvietota 1-azaoksacikloalkilgrupa, kur aizvietotājs ir izvēlēts no: 2-(Ci-C3)alkilmorfolinilgrupa; [1,n]-diazacikloalkil- un aizvietota [1 ,n]-diazacikloalkilgrupas, kas izvēlētas no: piperazinil- un 4-(Ci-C3)alkilpiperazinilgrupa; 1- azatiacikloalkil- un aizvietotas 1-azatiacikloalkilgrupas, kas izvēlētas no: tiomorfolinil- un 2-(CrC3)alkiltiomorfolinilgrupa; (heterocikla)metilaminogrupa, kas izvēlēta no: 2- vai 3-tienilmetilamino- un 2-, 3- vai 4-piridilmetilaminogrupa; 1,1-divaizvietota hidrazīnogrupa, kas izvēlēta no: 1,1-dimetilhidrazino- un N-aminopiperidinilgrupa; [β vai y-(CrC3)acilamido]alkilaminogrupas aizvietotājs, kas izvēlēts no: 2-(acetamido)etilgrupa; β vai y-(CrC3)aloksialkilaminogrupas aizvietotājs, kas izvēlēts no rindas: 2-metoksietil-, 2-etoksietil-, 2,2-dietoksietil-, 2- metoksipropil- un 3-metoksipropilgrupa; β, γ vai 5-(C2-C4)hidroksialkilaminogrupas aizvietotājs, kas izvēlēts no: 4-hidroksibutilgrupa un 3- hidroksipropil; vai R3 un W kopā ir izvēlēti no -(CH2)n(R5)N-, n=3, un R5 izvēlēts no: ūdeņradis un fluoroacetilgrupa; R6 ir izvēlēts no: ūdeņradis, lineāra vai sazarota (Ci-C3)alkilgrupa, kas izvēlēta no rindas: metil-, etil-, n-propil- vai 1-metiletilgrupa; R7 ir izvēlēts no: ūdeņradis, lineāra vai sazarota (CrC3)alkilgrupa, kas izvēlēta no rindas: metil-, etil-, n-propil- vai 1-metiletilgrupa, ar nosacījumu, ka R6 un R7 abi nevar būt ūdeņradis; vai R6 un R7 kopā ir -(CH2)2B(CH2)2-, kur B ir izvēlēts no rindas: (CH2)n un n=0-1, -NH, -N(CrC3)alkil[lineāra vai sazarotajgrupa, -N(Ci-C4)alkoksigrupa, skābeklis, sērs vai aizvietoti radnieciski savienojumi, kas izvēlēti no rindas: (L vai D) prolīns, etil(L vai Djprolināts, morfolīns, pirolidīns vai piperidīns; un farmaceitiski pieņemamiem organiskiem un neorganiskiem sāļiem vai metālu kompleksajiem savienojumiem. 1G
  2. 3. Savienojums saskaņā ar 1. un 2. punktiem, kur minētie sāļi vai kompleksie savienojumi ietver: hlorūdeņraž-, bromūdeņraž-, jodūdeņraž- un fosforskābes atvasinājums, nitrāts, sulfāts, acetāts, benzoāts, citrāts, cisteīns, fumarāts, glikolāts, maleāts, sukcināts, tartrāts, alkilsulfonāts, arilsulfonāts, alumīnijs, 5 kalcijs, dzelzs, magnijs vai mangāns.
  3. 4. Savienojums saskaņā ar 1. punktu, [4S-(4alfa, 12aalfa)]-9-[[[(Ciklopropilmetil)amino]-acetil]amino]-4,7-īo bis(dimetilamino)-1,4,4a,5,5a,6,11,12a-oktahidro-3,10,12,12a- tetrahidroksi-1,11-diokso-2-naftacēnkarboksamīda dihidrohlorīds; [4S-(4alfa, 12aalfa)]-9-[[[(2,2-dietoksietil)amino]-acetil]amino]-4,7-bis(dimetilamino)-1,4,4a,5,5a,6,11 ,-12a-oktahidro-3,10,12,12a-15 tetrahidroksi-1,11-diokso-2-naftacēnkarboksamīda dihidrohlorīds; [4S-(4alfa, 12aalfa)]- 4,7-Bis(dimetilamino)-1,4,4a,-5,5a,6,11,12a-oktahidro-3,10,12,12a-tetrahidroksi-9-[[[(2,2-metoksietil)amino]acetil]amino]-1,11 -diokso-2-naftacēnkarboksamīda 20 dihidrohlorīds; [4S-(4alfa, 12aalfa)]- 4,7-Bis(dimetilamino)-1,4,4a,-5,5a,6,11,12a-oktahidro-3,10,12,12a-tetrahidroksi-1,11 -diokso-9-[[(2,2-propenilamino)-acetiljamino]- 2-naftacēnkarboksamīda dihidrohlorīds; 25 [4S-(4alfa, 12aalfa)]- 4,7-Bis(dimetilamino)-1,4,4a,-5,5a,6,11,12a-oktahidro-3,10,12,12a-tetrahidroksi-9-[[[(3- metoksipropil)amino]acetil]amino]-1,11 -diokso-2-naftacēnkarboksamīda dihidrohlorīds; [7S-(7alfa, 10aalfa)]- N-[9-(Aminokarbonil)-4,7-bis-(dimetilamino)- 5,5a,6,6a,7,10,10a, 12-oktahidro-1,8,-10a, 11 -tetrahidroksi-10,12-diokso-2- naftacenil]-4-tiomorfolīnacetamīda dihidrohlorīds; 30 11 LV 12358 [7S-(7alfa, 10aalfa)]- N-[9-(Aminokarbon!i)-4,7-bis-(dimetilamino)- 5,5a,6,6a, 7,10,10a, 12-oktahidro-1,8,-10a, 11 -tetrahidroksi-10,12-diokso-2- naftacenil]-4-metil-1 -piperidīnacetamīda dihidrohlorīds; [7S-(7alfa, 10aalfa)]- N-[9-(Aminokarbonil)-4,7-bis(dimetilamino)-5,5a,6,6a,7,10,10a,12-oktahidro-1,8,-10a,11-tetrahidroksi-10,12-diokso-2-naftacenil]-4-metil-1-piperazīnacetamīda dihidrohlorīds; [4S-(4alfa, 12aalfa)]- 4,7-Bis(dimetilamino)-9-[[(heptilamino)acetil]amino]-1,4,4a, 5,5a,6,11,12a-oktahidro-3,10,12,12a-tetrahidroksi-1,11 -diokso-2-naftacēnkarboksamīda dihidrohlorīds; [4S-(4alfa, 12aalfa)]- 4,7-Bis(dimetilamino)-1,4,4a,-5,5a,6,11,12a-oktahidro-3,10,12,12a-tetrahidroksi-1,11 -diokso-9-[[(undecilamino)acetil]amino]- 2-naftacēnkarboksamīda dihidrohlorīds; [4S-(4alfa, 12aalfa)]- 4,7-Bis(dimetilamino)-1,4,4a,-5,5a,6,11,12a-oktahidro-3,10,12,12a-tetrahidroksi-1,11 -diokso-9-[[[(2-piridinilmetil)amido]acetil]amino]- 2-naftacēnkarboksamīda dihidrohlorīds; [4S-(4alfa, 12aalfa)]- 4,7-Bis(dimetilamino)-1,4,4a,5,5a,6,11,12a-oktahidro-3,10,12,12a-tetrahidroksi-9-[[[(2-hidroksietil)amino]acetil]-amino]-1,11-diokso-2-naftacēnkarboksamīda monohidrohlorīds; [4S-(4alfa, 12aalfa)]- 4,7-Bis(dimetilamino)-1,4,4a,-5,5a,6,11,12a-oktahidro-3,10,12,12a-tetrahidroksi-9-[[[(2- hidroksietil)metilamino]acetil]amino]-1,11 -diokso-2-naftacēnkarboksamīds; [4S-(4alfa, 12aalfa)]- 4,7-Bis(dimetilamino)-1,4,4a,-5,5a,6,11,12a-oktahidro-3,10,12,12a-tetrahidroksi-9-[[[(4- hidroksibutil)amino]acetil]amino]-1,11-diokso-2-naftacēnkarboksamīds; 12 [4S-(4alfa, 12aalfa)]- 4I7-Bis(dimetilamino)-1I4l4a,-5,5a,6l11,12a-oktahidro-3,10,12,12a-tetrahidroksi-1,11-diokso-9-[[[(2,2,2-trifluoretil)amino]acetil]amino]- 2-naftacēnkarboksamīds; 5 [4S-(4alfa, 12aalfa)]- 4,7-Bis(dimetilamino)-1,4,4a,-5,5a,6,11,12a- oktahidro-3,10,12,12a-tetrahidroksi-1,11-diokso-9-[[[[(2-(1-piperidinil)etil]amino]acetil]amino]- 2-naftacēnkarboksamTds; [4S-(4alfa, 12aalfa)]- 4,7-Bis(dimetilamino)-1,4,43,-5,58,6,11,12a-īo oktahidro-3,10,12,12a-tetrahidroksi-9-[[[metil-2- propinilamino]acetil]amino]-1,11 -diokso-2-naftacēnkarboksamīds; [4S-(4alfa, 12aalfa)]- 4,7-Bis(dimetilamino)-1,4,4a,-5,5a,6,11,12a-oktahidro-3,10,12,12a-tetrahidroksi-1,11 -diokso-9-[[(1 -15 piperidinilamino)acetil]amino]- 2-naftacēnkarboksamīds; vai [4S-(4alfa, 12aalfa)]- 4,7-Bis(dimetilamino)-1,4,4a,5,5a,6,11,12a-oktahidro-3,10,12,12a-tetrahidroksi-1,11 -diokso-9-[[[(fenilmetoksi)-amino]acetil]amino]- 2-naftacēnkarboksamīds. 20
  4. 5. Savienojums saskaņā ar 1. punktu izmantošanai paņēmienā, kurš aizsargā pret vai kontrolē siltasiņu dzīvnieku inficēšanos ar baktērijām.
  5. 6. Farmaceitiska vielu kompozīcija, kas ietver farmakoloģiski efektīvu 25 savienojuma saskaņā ar 1. punktu daudzumu kombinācijā ar farmaceitiski pieņemamu nesēju.
  6. 7. Veterināra kompozīcija, kas ietver farmakoloģiski efektīvu savienojuma saskaņā ar 1. punktu daudzumu un farmaceitiski pieņemamu nesēju. 30
  7. 8. Savienojums saskaņā ar 1. punktu izmantošanai paņēmienā, kurš aizsargā pret, ārstē vai kontrolē siltasiņu dzīvnieku inficēšanos ar baktērijām, kuru izraisa baktērijas ar TetM un TetK rezistantiem determinantiem. 13 13 LV 12358
  8. 9. Ražošanas paņēmiens savienojumam ar formulu I kā aprakstīts 1. punktā, kas ietver attiecīgā 9-[(haloacil)amido]-7-(aizvietota)-6-demetil-6-deoksitetraciklīna, vai organiskas vai neorganiskas sāls, vai metāla kompleksā savienojuma, ar formulu:
    , kur Y ir hlors, broms, fluors vai jods, reakciju ar nukleofīlu reaģentu ar formulu WH, kur W ir definēts 1. punktā, īo polārā aprotonā šķīdinātājā un inertā atmosfērā.
LVP-99-112A 1992-08-13 1999-07-26 7-(aizvietoti)-9-(aizvietoti glicil)-amido-6-demetil-6-deoksitetraciklīni LV12358B (lv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/928,589 US5328902A (en) 1992-08-13 1992-08-13 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines

Publications (2)

Publication Number Publication Date
LV12358A LV12358A (lv) 1999-10-20
LV12358B true LV12358B (lv) 2000-01-20

Family

ID=25456485

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-99-112A LV12358B (lv) 1992-08-13 1999-07-26 7-(aizvietoti)-9-(aizvietoti glicil)-amido-6-demetil-6-deoksitetraciklīni

Country Status (26)

Country Link
US (5) US5328902A (lv)
EP (1) EP0582788B1 (lv)
JP (1) JP3583449B2 (lv)
KR (1) KR100309539B1 (lv)
CN (1) CN1034216C (lv)
AT (1) ATE168992T1 (lv)
AU (1) AU674690B2 (lv)
CA (1) CA2103836C (lv)
CZ (1) CZ288152B6 (lv)
DE (1) DE69319976T2 (lv)
DK (1) DK0582788T3 (lv)
ES (1) ES2119831T3 (lv)
FI (1) FI115523B (lv)
HK (1) HK1009598A1 (lv)
HU (2) HUT64943A (lv)
IL (3) IL119118A (lv)
LV (1) LV12358B (lv)
MX (1) MX9304647A (lv)
NO (1) NO302359B1 (lv)
NZ (1) NZ248357A (lv)
PH (1) PH30007A (lv)
PL (3) PL174116B1 (lv)
RU (1) RU2125986C1 (lv)
SG (1) SG47559A1 (lv)
SK (1) SK281705B6 (lv)
ZA (1) ZA935894B (lv)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40183E1 (en) 1991-10-04 2008-03-25 Wyeth Holdings Corporation 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US5494903A (en) * 1991-10-04 1996-02-27 American Cyanamid Company 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
SG47520A1 (en) * 1992-08-13 1998-04-17 American Cyanamid Co New method for the production of 9-amino-6-demethyl-6-deoxytetracycline
US5284963A (en) * 1992-08-13 1994-02-08 American Cyanamid Company Method of producing 7-(substituted)-9-[(substituted glycyl)-amidol]-6-demethyl-6-deoxytetra-cyclines
US5442059A (en) * 1992-08-13 1995-08-15 American Cyanamid Company 9-[(substituted glycyl)amido)]-6-demethyl-6-deoxytetracyclines
US5420272A (en) * 1992-08-13 1995-05-30 American Cyanamid Company 7-(substituted)-8-(substituted)-9-](substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5371076A (en) * 1993-04-02 1994-12-06 American Cyanamid Company 9-[(substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines
JP2784847B2 (ja) * 1994-02-17 1998-08-06 ファイザー インク． ９−（置換アミノ）−アルファ−６−デオキシ−５−オキシテトラサイクリン誘導体、それらの製造及び、抗生物質としてのそれらの使用
US5675030A (en) * 1994-11-16 1997-10-07 American Cyanamid Company Method for selective extracting a 7-(hydrogen or substituted amino)-9- (substituted glycyl) amido!-6-demethyl-6-deoxytetracycline compound
US5843925A (en) * 1994-12-13 1998-12-01 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
IL137445A0 (en) * 1998-01-23 2001-07-24 Tufts College Pharmaceutically active compounds and methods of use thereof
US8106225B2 (en) * 1999-09-14 2012-01-31 Trustees Of Tufts College Methods of preparing substituted tetracyclines with transition metal-based chemistries
US6946118B1 (en) 1999-09-14 2005-09-20 Orapharma, Inc. Formulations for treating or preventing mucositis
CN102336680A (zh) * 1999-09-14 2012-02-01 塔夫茨大学信托人 用基于过渡金属的化学制备取代四环素的方法
WO2001074761A1 (en) * 2000-03-31 2001-10-11 Trustees Of Tufts College 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline compounds
US20020132798A1 (en) * 2000-06-16 2002-09-19 Nelson Mark L. 7-phenyl-substituted tetracycline compounds
WO2001098236A2 (en) * 2000-06-16 2001-12-27 Trustees Of Tufts College 7-phenyl-substituted tetracycline compounds
KR100699390B1 (ko) * 2000-07-07 2007-03-28 트러스티즈 오브 터프츠 칼리지 9-치환된 미노사이클린 화합물
CN102336679A (zh) * 2000-07-07 2012-02-01 塔夫茨大学信托人 7-取代的四环素化合物
US7094806B2 (en) 2000-07-07 2006-08-22 Trustees Of Tufts College 7, 8 and 9-substituted tetracycline compounds
US7553828B2 (en) 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
WO2002072506A2 (en) * 2001-03-13 2002-09-19 Paratek Pharmaceuticals, Inc. 7-pyrollyl tetracycline compounds and methods of use thereof
MXPA03008165A (es) * 2001-03-13 2003-12-12 Paratek Pharm Innc Compuestos tetraciclina sustituidos en la posicion 7,9.
EP1241160A1 (en) * 2001-03-13 2002-09-18 Glaxo Group Limited Tetracycline derivatives and their use as antibiotic agents
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
WO2003005971A2 (en) 2001-07-13 2003-01-23 Paratek Pharmaceuticals, Inc. Tetracycline compounds having target therapeutic activities
WO2003055441A2 (en) 2001-08-02 2003-07-10 Paratek Pharmaceuticals, Inc. Medicaments
EP1474380A4 (en) * 2002-01-08 2007-04-18 Paratek Pharm Innc 4-DESDIMETHYL AMINO TETRA CYCLINE COMPOUNDS
EA200802365A1 (ru) * 2002-03-08 2009-08-28 Паратек Фармасьютикалс, Инк. Аминометилзамещенные тетрациклиновые соединения
EP1503981A4 (en) 2002-03-21 2007-08-15 Paratek Pharm Innc SUBSTITUTED TETRACYCLINE COMPOUNDS
WO2004000223A2 (en) * 2002-06-20 2003-12-31 Orapharma, Inc. Rapidly disintegrating formulations for treating or preventing mucositis
EP1534300A4 (en) 2002-07-12 2008-04-23 Paratek Pharm Innc TETRACYCLINE COMPOUNDS SUBSTITUTED IN 3, 10, AND 12A
EP1633774B1 (en) 2003-06-18 2010-02-17 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor
JP4733028B2 (ja) 2003-07-09 2011-07-27 パラテック ファーマシューティカルズ インコーポレイテッド 置換テトラサイクリン化合物
US20060287283A1 (en) * 2003-07-09 2006-12-21 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
UA83266C2 (en) 2003-12-08 2008-06-25 Уайет Oxazole derivatives of tetracyclines
EP1716101A1 (en) * 2004-01-15 2006-11-02 Paratek Pharmaceuticals, Inc. Aromatic a-ring derivatives of tetracycline compounds
EP1805134B1 (en) 2004-10-25 2012-06-20 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
EP2949644A3 (en) 2004-10-25 2016-04-20 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
US7534766B2 (en) 2004-11-05 2009-05-19 Wyeth Glucuronide metabolites and epimers thereof of tigecycline
US8088755B2 (en) * 2005-02-04 2012-01-03 Paratek Pharmaceuticals, Inc. 11a, 12-derivatives of tetracycline compounds
AU2006214543A1 (en) 2005-02-15 2006-08-24 Wyeth 9-substituted tetracyclines
AR057032A1 (es) * 2005-05-27 2007-11-14 Wyeth Corp Tigeciclina y metodos de preparacion
AR057649A1 (es) 2005-05-27 2007-12-12 Wyeth Corp Formas solidas cristalinas de tigeciclina y metodos para preparar las mismas
AR057033A1 (es) * 2005-05-27 2007-11-14 Wyeth Corp Tigeciclina y metodos para preparar 9-nitrominociclina
AR057034A1 (es) * 2005-05-27 2007-11-14 Wyeth Corp Metodos para purificar tigeciclina
AR057324A1 (es) * 2005-05-27 2007-11-28 Wyeth Corp Tigeciclina y metodos para preparar 9-aminominociclina
EP1910273A2 (en) * 2005-07-21 2008-04-16 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
WO2007075792A1 (en) * 2005-12-22 2007-07-05 Wyeth Methods of treating gastrointestinal tract infections with tigecycline
BRPI0620646A2 (pt) * 2005-12-22 2011-11-22 Wyeth Corp composição farmacêutica compreendendo tigeciclina e seu uso
US20070244335A1 (en) * 2006-04-17 2007-10-18 Teva Pharmaceutical Industries Ltd. Isolation of tetracycline derivatives
US8198470B2 (en) * 2006-04-24 2012-06-12 Teva Pharmaceutical Industries Ltd. Crystalline form II of tigecycline and processes for preparation thereof
ES2528202T3 (es) * 2006-04-24 2015-02-05 Teva Pharmaceutical Industries Ltd. Una forma cristalina de tigeciclina y procesos para su preparación
JP2009537139A (ja) 2006-05-15 2009-10-29 パラテック ファーマシューティカルズ インコーポレイテッド 置換されたテトラサイクリン化合物を用いて、遺伝子または遺伝子産物の発現を制御する方法
AR061485A1 (es) * 2006-06-15 2008-08-27 Serenex Inc Composiciones estabilizadas de tetraciclina
EP2251320A1 (en) * 2006-11-29 2010-11-17 Teva Pharmaceutical Industries Ltd. Crystalline form of tigecycline and processes for preparation thereof
US20080234504A1 (en) * 2006-11-30 2008-09-25 Evgeny Tsiperman Processes for preparation of 9-haloacetamidominocyclines
FR2912133B1 (fr) * 2007-02-01 2009-04-24 Univ Grenoble 1 Nouveaux derives indoliques,leurs procedes de preparation et leurs utilisations notamment en tant qu'antibacteriens
WO2008106234A1 (en) * 2007-03-01 2008-09-04 Teva Pharmaceutical Industries Ltd. Processes for purification of tigecycline
WO2009032326A1 (en) * 2007-09-07 2009-03-12 Dr. Reddy's Laboratories Ltd. New tetracycline derivatives as antiinfective agents
CA2706475C (en) 2007-11-29 2016-05-03 Actelion Pharmaceuticals Ltd Phosphonic acid derivates and their use as p2y12 receptor antagonists
KR101856178B1 (ko) 2008-08-08 2018-05-10 테트라페이즈 파마슈티컬스, 인코포레이티드 Ｃ７-플루오로 치환된 테트라시클린 화합물
WO2010129057A2 (en) 2009-05-08 2010-11-11 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
NO2470500T3 (lv) 2009-08-28 2018-03-03
CN103635456B (zh) * 2011-07-26 2016-03-09 山东亨利医药科技有限责任公司 替加环素衍生物
BR112015004523B1 (pt) 2012-08-31 2020-08-04 Tetraphase Pharmaceuticals, Inc Compostos de tetraciclina, composições farmacêuticas e seus usos
SG11201903327PA (en) 2016-10-19 2019-05-30 Tetraphase Pharmaceuticals Inc Crystalline forms of eravacycline

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE26271E (en) * 1967-09-26 Reductive alkylation process
US2482055A (en) * 1948-02-11 1949-09-13 American Cyanamid Co Aureomycin and preparation of same
US2997471A (en) * 1958-08-18 1961-08-22 Bristol Myers Co Tetracycline derivatives
US3007965A (en) * 1959-02-13 1961-11-07 American Cyanamid Co New tetracyclines produced by streptomyces aureofaciens
US3043875A (en) * 1959-10-22 1962-07-10 Pfizer & Co C Halogenated tetracycline derivatives and processes for their preparation
FR1430859A (lv) * 1960-05-23 1966-05-25
US3338963A (en) * 1960-10-28 1967-08-29 American Cyanamid Co Tetracycline compounds
US3502696A (en) * 1961-08-18 1970-03-24 Pfizer & Co C Antibacterial agents
US3829453A (en) * 1961-08-18 1974-08-13 Pfizer Octahydroanthracene-2-aminoacetic acids and esters and mixed anhydrides thereof
US3862225A (en) * 1961-08-18 1975-01-21 Pfizer D-ring substituted tetracyclines
US3509184A (en) * 1961-08-18 1970-04-28 Pfizer & Co C Anthracyclidine-acetic acid derivatives
US3697552A (en) * 1961-08-18 1972-10-10 Pfizer Anthracyclidine-acetic acid derivatives
US3772363A (en) * 1961-08-18 1973-11-13 Pfizer 3,4,10-trioxo octahydroanthracene-2-aminoacetic acids and derivatives thereof
US3360557A (en) * 1963-05-10 1967-12-26 American Cyanamid Co 9-hydroxytetracyclines and a process of preparing same
USRE26253E (en) * 1963-05-17 1967-08-15 And z-alkylamino-g-deoxytetracycline
US3341585A (en) * 1966-05-06 1967-09-12 American Cyanamid Co Substituted 7-and/or 9-amino-6-deoxytetracyclines
US3515731A (en) * 1966-06-17 1970-06-02 Pfizer & Co C Antibacterial agents
US3849493A (en) * 1966-08-01 1974-11-19 Pfizer D-ring substituted 6-deoxytetracyclines
US3345410A (en) * 1966-12-01 1967-10-03 American Cyanamid Co Substituted 7- and/or 9-amino tetracyclines
US3360561A (en) * 1967-06-19 1967-12-26 American Cyanamid Co Nitration of tetracyclines
US3518306A (en) * 1968-02-19 1970-06-30 American Cyanamid Co 7- and/or 9-(n-nitrosoalkylamino)-6-demethyl-6-deoxytetracyclines
US4806529A (en) * 1982-11-18 1989-02-21 Trustees Of Tufts College, Tufts University Tetracycline activity enhancement
US5281628A (en) * 1991-10-04 1994-01-25 American Cyanamid Company 9-amino-7-(substituted)-6-demethyl-6-deoxytetracyclines
EP0536515B1 (en) * 1991-10-04 2001-12-19 American Cyanamid Company Novel 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US5284963A (en) * 1992-08-13 1994-02-08 American Cyanamid Company Method of producing 7-(substituted)-9-[(substituted glycyl)-amidol]-6-demethyl-6-deoxytetra-cyclines

Also Published As

Publication number Publication date
US5328902A (en) 1994-07-12
US5401729A (en) 1995-03-28
US5380888A (en) 1995-01-10
US5466684A (en) 1995-11-14
MX9304647A (es) 1994-02-28
CZ159993A3 (en) 1994-03-16
CZ288152B6 (en) 2001-05-16
JP3583449B2 (ja) 2004-11-04
PL174115B1 (pl) 1998-06-30
IL119118A0 (en) 1996-11-14
NO932869D0 (no) 1993-08-12
NO932869L (no) 1994-02-14
DE69319976T2 (de) 1999-03-25
HU9302330D0 (en) 1993-10-28
PL173904B1 (pl) 1998-05-29
CA2103836A1 (en) 1994-02-14
HUT64943A (en) 1994-03-28
PL300063A1 (en) 1994-02-21
SG47559A1 (en) 1998-04-17
JPH06206855A (ja) 1994-07-26
IL119118A (en) 1998-02-08
US5495031A (en) 1996-02-27
DK0582788T3 (da) 1999-02-01
FI933565A0 (fi) 1993-08-12
NZ248357A (en) 1996-04-26
KR100309539B1 (ko) 2002-08-31
IL106673A0 (en) 1993-12-08
CN1034216C (zh) 1997-03-12
ATE168992T1 (de) 1998-08-15
SK85693A3 (en) 1994-06-08
PL174116B1 (pl) 1998-06-30
HU211946A9 (en) 1996-01-29
ES2119831T3 (es) 1998-10-16
AU4461293A (en) 1994-02-17
PH30007A (en) 1996-10-29
CA2103836C (en) 2004-10-05
EP0582788B1 (en) 1998-07-29
FI115523B (fi) 2005-05-31
RU2125986C1 (ru) 1999-02-10
SK281705B6 (sk) 2001-07-10
NO302359B1 (no) 1998-02-23
KR940003924A (ko) 1994-03-14
IL106673A (en) 1997-11-20
EP0582788A1 (en) 1994-02-16
CN1083805A (zh) 1994-03-16
FI933565A (fi) 1994-02-14
HK1009598A1 (en) 1999-06-04
ZA935894B (en) 1994-03-09
DE69319976D1 (de) 1998-09-03
AU674690B2 (en) 1997-01-09
LV12358A (lv) 1999-10-20

Similar Documents

Publication Publication Date Title
LV12358B (lv) 7-(aizvietoti)-9-(aizvietoti glicil)-amido-6-demetil-6-deoksitetraciklīni
US5567692A (en) 9-[(substituted glycyl) amido)]-6-demethyl-6-deoxytetracyclines
US5371076A (en) 9-[(substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines
US5457096A (en) 7-(substituted)-8-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
HU211343A9 (hu) 7-(Szubsztituált)-8-(szubsztituált)-9-[(szubsztituált-glicil)-amido]- 6-dezmetil-6-dezoxitetraciklin-vegyületek